ErVaccine announced a collaboration with two US companies: EVOQ Therapeutics, for the development of synthetic HDL NanoDiscs to deliver cancer vaccine candidates and Oncovir for the rights to use their immune adjuvant Hiltonol to run an evaluation study. Over this agreement, ErVaccine will assess the interest of combining innovative tumor antigens, a breakthrough delivery technology and a potent adjuvant with the aim of enhancing vaccine-induced antitumor immune responses.
